Zurich Cantonal Bank’s Zenas BioPharma ZBIO Stock Holding History

Zurich Cantonal Bank’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$132K	Buy	+6,777	New	+$152K	﹤0.01%	2341

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Zurich Cantonal Bank's ZBIO Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 6,777 shares worth $132K. The stake represents ﹤0.01% of the portfolio and ranks #2341 among its holdings.

139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

Zurich Cantonal Bank held 6,777 shares of Zenas BioPharma worth $132K as of Q1 2026.
Zenas BioPharma was a new Zurich Cantonal Bank position in Q1 2026.
Zenas BioPharma made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #2341 holding.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.